Promoting Prevention and Targeting Remission of Asthma : A EUFOREA Consensus Statement on Raising the Bar in Asthma Care
(2025) In Chest 167(4). p.956-974- Abstract
Asthma is a common, multifaceted respiratory disease with a major impact on quality of life. Despite increased insights into mechanisms underlying various asthma phenotypes and endotypes and the availability of targeted biologic treatment options, the disease remains uncontrolled in a substantial proportion of patients with risk of exacerbations, requiring systemic corticosteroids, and with progressive disease. Current international guidelines advocate for a personalized management approach to patients with uncontrolled severe asthma. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) asthma expert panel was convened to discuss strategies to optimize asthma care and to prevent systemic corticosteroid... (More)
Asthma is a common, multifaceted respiratory disease with a major impact on quality of life. Despite increased insights into mechanisms underlying various asthma phenotypes and endotypes and the availability of targeted biologic treatment options, the disease remains uncontrolled in a substantial proportion of patients with risk of exacerbations, requiring systemic corticosteroids, and with progressive disease. Current international guidelines advocate for a personalized management approach to patients with uncontrolled severe asthma. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) asthma expert panel was convened to discuss strategies to optimize asthma care and to prevent systemic corticosteroid overuse and disease progression. In this meeting report, we summarize current concepts and recommendations and provide a rationale to implement personalized asthma management at earlier stages of the disease. The ultimate goal is to move away from the current one-size-fits-most concept, which focuses on a symptom-driven treatment strategy, and shift toward a phenotype- and endotype-targeted approach aimed at curbing the disease course by improving clinical outcomes and preserving health-related quality of life. Herein, we provide a consensus view on asthma care that advocates a holistic approach and highlight some unmet needs to be addressed in future clinical trials and population studies.
(Less)
- author
- organization
- publishing date
- 2025-04
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- allergen immunotherapy, asthma management, biologics, biomarkers, comorbidities, disease modification, prevention, remission
- in
- Chest
- volume
- 167
- issue
- 4
- pages
- 19 pages
- publisher
- American College of Chest Physicians
- external identifiers
-
- scopus:105000921724
- pmid:39672229
- ISSN
- 0012-3692
- DOI
- 10.1016/j.chest.2024.11.035
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2024 The Author(s)
- id
- 222fc00a-7108-4720-84fa-1f1cfc7e0719
- date added to LUP
- 2025-12-05 13:15:00
- date last changed
- 2025-12-05 13:15:37
@article{222fc00a-7108-4720-84fa-1f1cfc7e0719,
abstract = {{<p>Asthma is a common, multifaceted respiratory disease with a major impact on quality of life. Despite increased insights into mechanisms underlying various asthma phenotypes and endotypes and the availability of targeted biologic treatment options, the disease remains uncontrolled in a substantial proportion of patients with risk of exacerbations, requiring systemic corticosteroids, and with progressive disease. Current international guidelines advocate for a personalized management approach to patients with uncontrolled severe asthma. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) asthma expert panel was convened to discuss strategies to optimize asthma care and to prevent systemic corticosteroid overuse and disease progression. In this meeting report, we summarize current concepts and recommendations and provide a rationale to implement personalized asthma management at earlier stages of the disease. The ultimate goal is to move away from the current one-size-fits-most concept, which focuses on a symptom-driven treatment strategy, and shift toward a phenotype- and endotype-targeted approach aimed at curbing the disease course by improving clinical outcomes and preserving health-related quality of life. Herein, we provide a consensus view on asthma care that advocates a holistic approach and highlight some unmet needs to be addressed in future clinical trials and population studies.</p>}},
author = {{Jesenak, Milos and Bobcakova, Anna and Djukanovic, Ratko and Gaga, Mina and Hanania, Nicola A. and Heaney, Liam G. and Pavord, Ian and Quirce, Santiago and Ryan, Dermot and Fokkens, Wytske and Conti, Diego and Hellings, Peter W. and Scadding, Glenis and Van Staeyen, Elizabeth and Bjermer, Leif H. and Diamant, Zuzana}},
issn = {{0012-3692}},
keywords = {{allergen immunotherapy; asthma management; biologics; biomarkers; comorbidities; disease modification; prevention; remission}},
language = {{eng}},
number = {{4}},
pages = {{956--974}},
publisher = {{American College of Chest Physicians}},
series = {{Chest}},
title = {{Promoting Prevention and Targeting Remission of Asthma : A EUFOREA Consensus Statement on Raising the Bar in Asthma Care}},
url = {{http://dx.doi.org/10.1016/j.chest.2024.11.035}},
doi = {{10.1016/j.chest.2024.11.035}},
volume = {{167}},
year = {{2025}},
}